ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets

ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets

Abstract Vaccines against SARS-CoV-2 are likely to be critical in the management of the ongoing pandemic. A number of candidates are in Phase III human clinical trials, including ChAdOx1 nCoV-19 (AZD1222), a replication-deficient chimpanzee adenovirus-vectored vaccine candidate. In preclinical trial...

Full description

Bibliographic Details
Main Authors: Glenn A. Marsh, Alexander J. McAuley, Gough G. Au, Sarah Riddell, Daniel Layton, Nagendrakumar B. Singanallur, Rachel Layton, Jean Payne, Peter A. Durr, Hannah Bender, Jennifer A. Barr, John Bingham, Victoria Boyd, Sheree Brown, Matthew P. Bruce, Kathie Burkett, Teresa Eastwood, Sarah Edwards, Tamara Gough, Kim Halpin, Jenni Harper, Clare Holmes, William S. J. Horman, Petrus Jansen van Vuren, Suzanne Lowther, Kate Maynard, Kristen D. McAuley, Matthew J. Neave, Timothy Poole, Christina Rootes, Brenton Rowe, Elisha Soldani, Vittoria Stevens, Cameron R. Stewart, Willy W. Suen, Mary Tachedjian, Shawn Todd, Lee Trinidad, Duane Walter, Naomi Watson, Trevor W. Drew, Sarah C. Gilbert, Teresa Lambe, S. S. Vasan
Format: Article
Language:English
Published: Nature Publishing Group 2021-05-01
Series:npj Vaccines
Online Access:https://doi.org/10.1038/s41541-021-00315-6

Internet

https://doi.org/10.1038/s41541-021-00315-6

Similar Items